Overview
Provider of high-performance scientific instruments and solutions.
Deals · 12mo
0
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Mercy BioAnalytics | Sep 2025Participated | $59 MSeries B | |
Terrain Biosciences | Feb 2025Participated | $9 MSeed | |
Akribion Therapeutics | Feb 2025Participated | $9 MSeed | |
PrognomiQ | Nov 2024Participated | $34 MSeries D | |
Tome Biosciences | Dec 2023Participated | $213 MSeries A | |
Mercy BioAnalytics | Apr 2023Participated | $41 MSeries A | |
KIYATEC | Dec 2022Led | $18 MSeries C | |
Haystack Oncology | Nov 2022Participated | $56 MSeries A | |
Navignostics | Nov 2022Led | $8 MSeed | |
Acuamark Diagnostics | Jul 2022Participated | $11 MSeries A | |
PrognomiQ | Mar 2022Led | $46 MOther Equity | |
PreOmics | Jan 2022Led | $15 MSeries B | |
Mercy BioAnalytics | Sep 2025Participated | $59 MSeries B | |
Terrain Biosciences | Feb 2025Participated | $9 MSeed | |
Akribion Therapeutics | Feb 2025Participated | $9 MSeed | |
PrognomiQ | Nov 2024Participated | $34 MSeries D | |
Tome Biosciences | Dec 2023Participated | $213 MSeries A | |
Mercy BioAnalytics | Apr 2023Participated | $41 MSeries A | |
KIYATEC | Dec 2022Led | $18 MSeries C | |
Haystack Oncology | Nov 2022Participated | $56 MSeries A | |
Navignostics | Nov 2022Led | $8 MSeed | |
Acuamark Diagnostics | Jul 2022Participated | $11 MSeries A | |
PrognomiQ | Mar 2022Led | $46 MOther Equity | |
PreOmics | Jan 2022Led | $15 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 2 |
| Series A | 0 | 4 |
| Series B | 1 | 2 |
| Series C+ | 1 | 1 |
| Other Equity | 1 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '20 | 2 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 1 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 1 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 2 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 1 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 2 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 14 |
| Enterprise Software | 1 |
| Data, Analytics & IT | 1 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 3 |
| $10M-$25M | 4 |
| $25M-$50M | 3 |
| $50M-$100M | 3 |
| $100M-$250M | 1 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 11 |
| Europe | 3 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| aMoon | 3 |
| Catalio Capital Management | 3 |
| Invus | 3 |
| Labcorp | 3 |
| Alexandria Venture Investments | 2 |
| BrightEdge Ventures | 2 |
| Emerson Collective | 2 |
| Fidelity Management & Research Company | 2 |
| High-Tech Grunderfonds | 2 |
| iSelect Fund | 2 |
| Maverick Ventures | 2 |
| Sozo Ventures | 2 |
| T. Rowe Price Associates | 2 |
| Think.Health Ventures | 2 |
| Wing Venture Capital | 2 |
| Andreessen Horowitz | 1 |
| ARCH Venture Partners | 1 |
| Avestria Ventures | 1 |
| Bio + Health | 1 |
| Broadway Angels | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 4 | 29% |
| Participating | 10 | 71% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 4 | 100% |
| Co-led | 0 | 0% |
Team
President & CEO
Founder
Vice President, Financial Planning and Analysis
Director Of Customer Service
President
EVP
Service Operations Manager
